GLP-1 Receptor Agonists have an Additional Role for Headache Relief
Exenatide, a GLP-1 agonist sold under the brand names Byetta and Bydureon by AstraZeneca (LSE: AZN) as a type 2 diabetes drug, could be useful in another indication, a trial has found.
This study, published in the journal Brain, reports on a Phase II trial of the drug as a potential treatment for severe headaches known as idiopathic intercranial hypertension (IIH).
Central sensitization is considered a critical pathogenic mechanism of chronic migraine (CM). Activation of microglia in the trigeminal nucleus caudalis (TNC) contributes to this progression. Microglial glucagon-like peptide-1 receptor (GLP-1R) activation can alleviate pain. Microglial GLP-1R activation in the TNC may suppress the central sensitization of CM by regulating TNC microglial activation via the PI3K/Akt pathway.
What is idiopathic intracranial hypertension?
Idiopathic intracranial hypertension (IIH) is a disorder related to high pressure in the brain. It causes signs and symptoms of a brain tumor. It's also sometimes called pseudotumor cerebri or benign intracranial hypertension.
The fluid that surrounds the spinal cord and brain is called cerebrospinal fluid or CSF. If too much fluid is made or not enough is re-absorbed, the CSF can build up. This can cause symptoms like those of a brain tumor.
What causes idiopathic intracranial hypertension?
Specialists do not know why IIH occurs. Obesity is a risk factor. Some medicines have been linked to a higher risk of it. These include common medicines like:
-
Birth control pills
-
Certain antibiotics
-
Chemotherapy medicines
-
Steroids
-
Some acne medicines
If you are suffering from IIH or suspect that you may have it, Please consult a Neurologist ASAP.